Condition
Marginal Zone B Cell Lymphoma
Total Trials
5
Recruiting
1
Active
1
Completed
1
Success Rate
33.3%-53% vs avg
Key Insights
Highlights
Success Rate
33% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
Termination Rate
40.0%
2 terminated out of 5 trials
Success Rate
33.3%
-53.2% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results33% success
Data Visualizations
Phase Distribution
4Total
P 1 (3)
P 2 (1)
Trial Status
Terminated2
Not Yet Recruiting1
Completed1
Recruiting1
Trial Success Rate
33.3%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT03919175Phase 2Terminated
Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma
NCT07024147Phase 1Not Yet Recruiting
JWCAR239 in Patients With B Cell Non-Hodgkin Lymphoma
NCT06806488RecruitingPrimary
Study to Assess Clinical Characteristics and Outcome of Patients with Marginal Zone Lymphomas
NCT02914938Phase 1Terminated
A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma
NCT01460134Phase 1Completed
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
Showing all 5 trials